Novozymes A/S

Novozymes A/S has been granted 770 US utility patents between 2015 and 2025, placing Novozymes A/S at rank #581 across all assignees tracked by PlainPatent. This portfolio spans 73 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Novozymes A/S is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 63.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 392 grants, compared with 378 in the 2015–2019 window — a +4% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Novozymes A/S's 18.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 73 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novozymes A/S against peers pursuing similar technology classes.